Detecting nucleic acids and proteins have been is made possible by the historic and revolutionary technologies like Polymerase Chain Reaction (PCR) and ELISA. PCR currently cannot be applied to non-nucleic biomolecules and ELISA has limited sensitivity. Immuno-PCR is another powerful technology that combines PCR and ELISA. This technology is an advancement over the immuno-PCR detection technique using DNA- Avidin in reporter nanoparticles. The multi template DNA-Avidin nanoparticles created have specific sensitivity to multiple biotin binding sites. The assay results in 100X more sensitivity compared to currently used immuno-assays.
- Detection of specific non-nucleic biomolecules including hormones, biomarkers, toxins etc.
- PCR is a highly sensitive assay, however it only works in the presence of nucleic acids
- ELISA is applicable for hormone, antibodies, proteins toxins, however has lower sensitivity than PCR
- Immuno-PCR combines the specificity of an ELISA with the signal amplification of PCR. However, its sensitivity is not adequate for the detection of analytes of low abundance
- Immuno-PCR is a complex and expensive assay
- Highly sensitive and applicable to multiple biomolecules
- Avoids antibody-DNA conjugation
- Assay does not require fresh tissue biopsy
- Provisional patent filed